Date: May 31, 2026
Other Operational / Legal / Strategic Disclosures
MedPlus Health Services Limited discloses that its subsidiary, Optival Health Solutions Private Limited, has received two drug license suspension orders from Telangana state authorities:
First Suspension Order:
- Authority: Assistant Director, Drugs Control Administration, Nalgonda, Telangana
- Nature of Action: Suspension of Drug License for five days
- Store Location: Nareducharla Main Road, Telangana
- Date of Order Receipt: May 30, 2026
- Regulatory Violation: Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945
- Financial Impact: Potential Revenue Loss of ₹0.85 lakhs
Second Suspension Order:
- Authority: Assistant Director, Drugs Control Administration, Serilingampali, Telangana
- Nature of Action: Suspension of Drug License for two days
- Store Location: Laxmi Nagar Colony Hydershahkote Exp, Telangana
- Financial Impact: Potential Revenue Loss of ₹0.18 lakhs
Total Estimated Impact: Combined potential revenue loss of ₹1.03 lakhs from both suspension orders.
Regulatory Context: This disclosure is made pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024.
Document Availability: The disclosure will be available on the company's website (www.medplusindia.com) and on the websites of BSE Limited (www.bseindia.com) and National Stock Exchange of India Ltd. (www.nseindia.com).